FIGURE 7 from Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts

Synergy between TAK-243 and Venetoclax in organoids generated from patient-derived xenograft (PDXO). A, Representative brightfield images of PDXOs (20x magnification, scale bar 50 µm). B, Phenotypic characteristics of PDXOs. Expression of biomarkers routinely used to diagnose ACC, including inhibin-α, SF-1, INSM-1, and β-catenin in ACC-PDX-derived organoids using immunofluorescence assay. C, Top: The indicated ACC PDXOs were treated with TAK-243 with or without Venetoclax for 72 hours. Bottom: Plots of the corresponding CI values.